Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

July 29, 2021
12:36 pm

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

CAMBRIDGE, Mass. & MENLO PARK, Calif.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical…

Click here to view the original article.

Business Wire, Global

Share this article

Is There Now An Opportunity In DSV (CPSE:DSV) After Recent Share Price Weakness

February 16, 2026

Standard Chartered Cuts XRP Price Target 65% To $2.80 As Crypto Market Tumbles

February 16, 2026

Unpacking A 123% Potential Upside

February 16, 2026

Crypto News :Pepeto Presale Past $7.23 Million as AI Models Predict Bitcoin Could Hit $400,000

February 16, 2026

Is UiPath (PATH) Starting To Look Attractive After Recent Share Price Weakness

February 16, 2026

How Market Structure and Utility Influence Long-Term Crypto Valuations?

February 16, 2026

5 Stocks With Recent Price Strength Amid Wall Street Volatility – February 16, 2026

February 16, 2026

Australian investors narrowly avoid losses after local outpost of high-yield crypto platform was shelved

February 16, 2026